Acadia Pharmaceuticals Inc
ACAD
Get informed when a big investor buys or sells
+ FollowMarket Cap$5B
Close$
$-11.60
140.9% downside
Current Fair Value
140.9% downsideOvervalued by 140.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.00 Billion |
|---|---|
| Enterprise Value | $4.69 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.32 |
| Beta | 0.8 |
| Outstanding Shares | 171,603,000 |
Return
| Return on Equity | 29.12% |
|---|---|
| Return on Assets | 21.83% |
| Return on Invested Capital | 6.27% |
Valuation & Multiples
| P/E Ratio | 12.98 |
|---|---|
| PEG | 71.61 |
| Price to Sales | 4.73 |
| Price to Book Ratio | 4.05 |
| Enterprise Value to Revenue | 4.12 |
| Enterprise Value to EBIT | 54.13 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$295.83 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.20
Average shareholder expectationRevenue Estimate
$330.96 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 68.09% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.49%▼ 72.79% |
|---|---|
| Total Invested | $1.06B▼ 71.19% |
| Investors Holding | 136▼ 219.00% |
ESG Score
No data
About Acadia Pharmaceuticals Inc
CEO: Uli Hacksell